CVS Health Co. (NYSE:CVS) Receives Average Recommendation of “Buy” from Brokerages

CVS Health Co. (NYSE:CVSGet Rating) has been assigned a consensus recommendation of “Buy” from the twenty-two research firms that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $116.05.

Several analysts recently commented on the stock. StockNews.com assumed coverage on shares of CVS Health in a research note on Thursday, March 31st. They issued a “strong-buy” rating for the company. BMO Capital Markets lifted their target price on shares of CVS Health from $108.00 to $120.00 in a research report on Thursday, February 10th. Raymond James cut shares of CVS Health from a “strong-buy” rating to an “outperform” rating and lifted their target price for the stock from $115.00 to $120.00 in a research report on Friday, February 11th. Deutsche Bank Aktiengesellschaft lifted their target price on shares of CVS Health from $110.00 to $113.00 in a research report on Thursday, May 5th. Finally, Tigress Financial lifted their target price on shares of CVS Health from $122.00 to $125.00 in a research report on Thursday, April 7th.

Shares of NYSE:CVS traded up $0.70 during midday trading on Friday, hitting $97.15. The stock had a trading volume of 99,466 shares, compared to its average volume of 6,340,459. The company has a market capitalization of $127.39 billion, a PE ratio of 16.02, a P/E/G ratio of 1.47 and a beta of 0.78. The stock has a 50 day moving average price of $101.77 and a two-hundred day moving average price of $101.28. The company has a current ratio of 0.88, a quick ratio of 0.62 and a debt-to-equity ratio of 0.70. CVS Health has a 1 year low of $79.33 and a 1 year high of $111.25.

CVS Health (NYSE:CVSGet Rating) last issued its earnings results on Wednesday, May 4th. The pharmacy operator reported $2.22 earnings per share for the quarter, beating the consensus estimate of $2.14 by $0.08. CVS Health had a net margin of 2.67% and a return on equity of 15.33%. The business had revenue of $76.83 billion for the quarter, compared to the consensus estimate of $75.30 billion. During the same quarter in the previous year, the firm earned $2.04 earnings per share. The business’s quarterly revenue was up 11.2% compared to the same quarter last year. As a group, equities analysts expect that CVS Health will post 8.32 EPS for the current year.

The business also recently announced a quarterly dividend, which was paid on Monday, May 2nd. Investors of record on Friday, April 22nd were issued a $0.55 dividend. The ex-dividend date of this dividend was Thursday, April 21st. This represents a $2.20 dividend on an annualized basis and a yield of 2.26%. CVS Health’s payout ratio is 36.54%.

In other CVS Health news, EVP Prem S. Shah sold 16,954 shares of the business’s stock in a transaction that occurred on Friday, April 8th. The shares were sold at an average price of $105.00, for a total transaction of $1,780,170.00. Following the completion of the sale, the executive vice president now directly owns 43,453 shares in the company, valued at $4,562,565. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Daniel P. Finke sold 55,359 shares of the business’s stock in a transaction on Monday, April 4th. The stock was sold at an average price of $100.13, for a total transaction of $5,543,096.67. Following the transaction, the executive vice president now directly owns 3,098 shares in the company, valued at $310,202.74. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 82,283 shares of company stock valued at $8,376,142. 0.69% of the stock is owned by insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Macroview Investment Management LLC lifted its position in shares of CVS Health by 128.3% during the first quarter. Macroview Investment Management LLC now owns 242 shares of the pharmacy operator’s stock worth $25,000 after purchasing an additional 136 shares in the last quarter. West Bancorporation Inc. acquired a new stake in CVS Health in the fourth quarter valued at $25,000. Claremont Financial Group Inc. acquired a new stake in CVS Health in the fourth quarter valued at $26,000. Bell Investment Advisors Inc acquired a new stake in CVS Health in the third quarter valued at $26,000. Finally, Stuart Chaussee & Associates Inc. raised its holdings in CVS Health by 123.0% in the first quarter. Stuart Chaussee & Associates Inc. now owns 310 shares of the pharmacy operator’s stock valued at $31,000 after acquiring an additional 171 shares in the last quarter. 78.00% of the stock is currently owned by institutional investors and hedge funds.

CVS Health Company Profile (Get Rating)

CVS Health Corporation provides health services in the United States. The company's Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates.

Read More

Analyst Recommendations for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.